Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Agenus Inc. buy Vassago1

Start price
€0.54
28.04.23 / 50%
Target price
-
Performance (%)
-
End price
-
28.04.23
Summary
This prediction was cancelled by the user.

Agenus is a biotechnology company focused on developing immunotherapies to treat cancer and other diseases. The company's product pipeline includes checkpoint inhibitors, which work by blocking proteins that help cancer cells evade detection by the immune system, as well as other immunotherapies designed to stimulate the body's immune response to tumors. Agenus has collaborations with large pharmaceutical companies including Merck, Incyte, and Gilead, and is actively working on bringing its products to market through clinical trials and regulatory approval. The company is listed on the NASDAQ stock exchange under the ticker symbol AGEN.

Performance without dividends (%)
Name 1w 1m
Agenus Inc. 4.025% 4.025%
iShares Core DAX® 1.883% 5.122%
iShares Nasdaq 100 0.125% 2.574%
iShares Nikkei 225® -0.201% 4.341%
iShares S&P 500 0.728% 4.141%

According to Vassago1 what are the pros and cons of Agenus Inc. for the foreseeable future?

Pros
Could be very worthwhile Investment >20% year
Cons

Comments by Vassago1 for this prediction

In the thread Agenus Inc. diskutieren

Buy Agenus Inc.

In the thread Trading Agenus Inc.
Prediction Buy
Perf. (%) -
Target price
Change
Ends at

Buy beendet